Cellectis Stock Price, News & Analysis

Cellectis, a clinical-stage biotechnology company focused on gene editing, has announced its participation in four upcoming investor conferences. These events include Citi's 17th Annual Biopharma Conference on September 7, 2022, and the Wells Fargo 2022 Healthcare Conference from September 7-9, followed by presentations at the Baird Global Healthcare Conference on September 13 and the Jefferies Cell and Genetic Medicine Summit on September 29. Cellectis is dedicated to developing innovative therapies for cancer and genetic diseases using its proprietary TALEN® technology and aims to provide treatment options for various cancers.

Cellectis announced its share and voting rights update as of July 31, 2022. The total number of ordinary shares in circulation stands at 45,510,810, with total voting rights reaching 51,875,672. This report is part of compliance with the French financial markets authority regulations.

As a leading clinical-stage biotechnology company, Cellectis is focused on developing innovative cell and gene therapies utilizing its gene-editing technology, TALEN®, and aims to address unmet medical needs in oncology.

Cellectis has received FDA clearance for its IND application for UCART20x22, targeting Non-Hodgkin Lymphoma. With a cash position of $135 million as of June 30, 2022, the company is well-positioned for upcoming clinical trials. Cellectis is progressing in enrolling patients in three Phase 1 trials and plans to initiate the NatHaLi-01 clinical trial this year. However, the company reported a significant drop in revenue, from $43 million in the first half of 2021 to $7 million in 2022, primarily due to decreased collaboration income.

Cellectis announced FDA clearance for its IND application to initiate a Phase 1/2a clinical trial of UCART20x22 in patients with relapsed or refractory Non-Hodgkin Lymphoma (r/r NHL). This marks the company's first allogeneic dual CAR T product, targeting CD20 and CD22 simultaneously. The NatHaLi-01 study is set to begin patient enrollment in the latter half of this year. UCART20x22 will utilize TALEN® technology to enhance patient outcomes in treating B-cell malignancies, potentially broadening the addressable patient population.

Cellectis (Nasdaq: CLLS) announced it will report Q2 financial results on August 4, 2022, after market close. A conference call to discuss these results is scheduled for August 5, 2022, at 8:00 AM EDT, providing updates on business activities. The company specializes in gene-editing technology for cancer therapies, utilizing its TALEN® system and PulseAgile platform. With 22 years of expertise, Cellectis aims to address unmet medical needs in oncology and other diseases.

Cellectis, a clinical-stage biotechnology company, announced the publication of research on its immune-evasive universal CAR T-cells in Nature Communications. The data suggests that these CAR T-cells can evade the host immune system, potentially improving treatment for multiple malignancies. The engineered cells demonstrated effectiveness against alloresponsive attacks, showing prolonged anti-tumor activity. Cellectis aims to make these therapies widely available, enhancing patient outcomes in difficult-to-treat cancers. The research indicates a promising advance towards universal CAR T-cell therapies.

Cellectis, a clinical-stage biotechnology company, announced the appointment of two new Directors, Axel-Sven Malkomes and Donald Bergstrom, M.D., Ph.D., during its annual shareholders meeting on June 28, 2022. Both appointees bring extensive experience from the healthcare and financial sectors. Dr. Bergstrom serves as Executive Vice President at Relay Therapeutics and has previous roles at Mersana Therapeutics and Sanofi Oncology. Mr. Malkomes has over 25 years in the industry, previously serving as CFO at Medigene AG and holding senior positions at Barclays and Société Générale.

Cellectis S.A. hosted its Annual Shareholders’ General Meeting on June 28, 2022, in Paris, France, with 67.23% of voting rights exercised.

Resolutions 1 through 23 and 25 were approved, while resolutions 24 and 26 were rejected. Detailed voting results are available on the company's website.

Cellectis is a clinical-stage biotech company focused on developing gene therapies for various cancers and blood disorders using its TALEN gene-editing technology and PulseAgile system.

Cellectis, a clinical-stage biotechnology company, focuses on gene-editing therapies for cancer and blood disorders. As of May 31, 2022, the company has 45,510,810 shares and 51,103,546 voting rights. Utilizing TALEN® gene editing technology, Cellectis aims to develop allogeneic CAR-T immunotherapies for conditions like acute myeloid leukemia and multiple myeloma. With over 22 years of expertise, it is dedicated to creating transformative therapies. The company is listed on both the Nasdaq (CLLS) and Euronext Growth (ALCLS).